AI-generated summary
Forty-two children with acute myeloid leukemia receiving chemotherapy were randomly assigned to photobiomodulation or sham therapy, with both groups following standard oral mucositis prevention. The authors report that the laser group had a lower incidence and severity of oral mucositis at several follow-up points, and conclude that photobiomodulation effectively reduces it. The study is a single-center trial in Egypt.
- Participants
- 42
- Who or what was studied
- Children with acute myeloid leukemia receiving chemotherapy at Children's Cancer Hospital 57357, Cairo, Egypt
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract describes a single-center trial, and its reported results do not state follow-up adequacy, blinding procedures, or whether the findings were replicated.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Photobiomodulation, Laser, Photobiomodulation therapy, Control group, Effect size, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.